Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • crh
    Member
    • Dec 2009
    • 46

    #1

    DESeq2 experimental design/analysis

    Nieve statistical question

    We have the following data:
    control: 3 biological replicates
    treatment 1: 2 biological replicates
    treatment 2: 2 biological replicates

    Using DESeq2 and running 3 separate comparisons we get:
    1. ctl vs treatment 1 ~ 160 genes up-regulated
    2. ctl vs treatment 2 ~ 660 genes up-regulated
    3. treatment1 vs treatment 3 ~ NO genes up-regulated

    So, if we compare data from 1 & 2 we get ~ 500 genes differentiially up-regulated between treatment 1 : treatment2, but none if we compare them directly (#3).

    I assume this means T1 & T2 distributions are nearly identical, and differ from the control.

    Correct?

    Charles
  • dpryan
    Devon Ryan
    • Jul 2011
    • 3478

    #2
    I don't know about "nearly identical", but they're less likely to be different than the control condition (note my weird wording, which allows for cases where the variance in the treatment groups is high whereas that in the control group is low...which can also lead to findings like this). BTW, you probably want to check down-regulated genes as

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
      by SEQadmin2



      CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

      Despite this, “CRISPR helped turn genome editing from a specialized technique into
      ...
      07-31-2026, 11:01 AM
    • SEQadmin2
      Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
      by SEQadmin2


      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

      The systematic characterization of the human proteome has
      ...
      07-20-2026, 11:48 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, Today, 10:35 AM
    0 responses
    4 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 08-06-2026, 07:41 AM
    0 responses
    23 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 08-03-2026, 10:13 AM
    0 responses
    41 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-31-2026, 02:55 AM
    0 responses
    47 views
    0 reactions
    Last Post SEQadmin2  
    Working...